Play-by-play of Gilead­'s $21B Im­munomedics buy­out de­tails a fren­zied push — and mints a new biotech bil­lion­aire

Im­munomedics had not re­al­ly been look­ing for a buy­out when the year be­gan. Ex­cit­ed by its BLA for Trodelvy, sub­mit­ted to the FDA in late 2019, ex­ec­u­tive chair­man Be­hzad Ag­haz­adeh start­ed off look­ing for po­ten­tial li­cens­ing deals and ze­roed in on four po­ten­tial part­ners, in­clud­ing Gilead, fol­low­ing Jan­u­ary’s JP Mor­gan Health­care Con­fer­ence in San Fran­cis­co. Such talks ad­vanced through­out the year, with dis­cus­sions ad­vanc­ing to the sec­ond round in mid-Au­gust.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER